Recent Updates
Recently added Catalysts

Fluoxetine

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |Eli Lilly and Company|Last Updated: Nov 26, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials4
Total Enrollment1,776

FDA Designations

No designations recorded

Clinical trial landscape

Fluoxetine · 5 trials · 2 indications

Phase 3 5
NCT01808651A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term DosingMajor Depressive Disorder
COMPLETED200 Analytics
NCT01808612A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term DosingMajor Depressive Disorder
COMPLETED513 Analytics
NCT00958568A Study in Relapse Prevention of Treatment-Resistant DepressionTreatment Resistant Depression
COMPLETED892 Analytics
NCT00849693A Study in the Treatment of Children and Adolescents With Major Depressive DisorderMajor Depressive Disorder
COMPLETED463 Analytics
NCT00035321The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant DepressionMajor Depressive Disorder
COMPLETED600 Analytics
PHASE3COMPLETED
A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
A Study in Relapse Prevention of Treatment-Resistant Depression
Treatment Resistant DepressionUnlock trial analytics
PHASE3COMPLETED
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
Major Depressive DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Adverse Events (AEs) or Serious AEs (SAEs)
Baseline through Week 52.
Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)
Baseline through Week 52

C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.

Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score
Baseline, 6 weeks

HAMD21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 64 (severely depressed). Least squares (LS) means were calculated using mixed-model repeated measures (MMRM) adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline HAMD21 total score.

Time to Relapse by Any Criteria
Randomization (Week 20) to Week 47

Relapse defined as meeting any of these criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with a Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalized for depression or suicidality; Discontinued due to lack of efficacy/worsening of depression/suicidality. MADRS is a 10-item rating scale for depressive mood symptoms severity, items rated on 0-6 scale, with total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at discretion of investigator based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were "censored" at their last observation.

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint
Baseline, Week 10

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment\*visit, age category\*visit and baseline\*visit.

To assess the efficacy of up to 8 weeks of treatment with OFC versus olanzapine and fluoxetine monotherapies, in patients with recurrent MDD without psychotic features
who meet study criteria for TRD, as measured by last observation carried forward (LOCF) mean change from baseline to endpoint in the MADRS total score
Treatment-resistant depression will be defined as:historic failure to achieve satisfactory response to an antidepressant (other than fluoxetine) during the current MDD episode
when treated with an acceptable antidepressant drug and dose for at least 6 weeks
prospective failure to achieve a satisfactory response to fluoxetine monotherapy during the 8 week study lead-in phase

Secondary Endpoints

Mean Change From Baseline to Week 52 on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score
Baseline, Week 52
Percentage of Participants Achieving a Response at Week 52
Baseline, up to Week 52
Percentage of Participants Achieving a Remission at Week 52
up to Week 52
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
FluoxetineEXPERIMENTALFlexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks
20 mg FluoxetineEXPERIMENTAL20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
40 mg FluoxetineEXPERIMENTAL40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
PlaceboPLACEBO_COMPARATORPlacebo (capsules) administered orally, once daily, for 6 weeks
Olanzapine and Fluoxetine combination (OFC)EXPERIMENTAL -
Duloxetine 60 mgEXPERIMENTAL -
Duloxetine 30 mgEXPERIMENTAL -

Interventions

NameTypeDescription
FluoxetineDRUGAdministered orally
PlaceboDRUG -
Olanzapine and Fluoxetine combination (OFC)DRUGOpen label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks. Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks. Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks.
duloxetineDRUG60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
OlanzapineDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range20 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Have completed Study B1Y-JE-HCLV (NCT#:NCT01808612) * Agree to abstain from sexual activity or to use a reliable method of birth control Exclusion Criteria: * Significant suicidal risk * Have a current or previous diagnosis of bipolar disorder, psychotic depression, schizoph...

Countries:JapanUnited StatesArgentinaIndiaMexicoPuerto RicoRussiaSouth AfricaTurkey (Türkiye)Canada
Unlock Eligibility Criteria